Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02055963 | Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer | terminated | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02408887 | Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 27, 2022 | clinicaltrials |
| NCT03930771 | Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas(TMZ-Cap) | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT00394147 | Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer | terminated | Phase 2 | 17 | Fox Chase Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT02325349 | PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents(MLAPOCHI) | terminated | Phase 2 | 1 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT03090412 | Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04880603 | Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site | terminated | Phase 2 | 5 | Nebraska Methodist Health SystemOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT04428047 | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma(ICING) | terminated | Phase 2 | 7 | UNICANCEROTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04015336 | E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2022 | clinicaltrials |
| NCT01606566 | A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer. | terminated | Phase 2 | 26 | PCI Biotech ASINDUSTRY | 6 | Feb 18, 2022 | clinicaltrials |
| NCT00003777 | Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer | terminated | Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02874651 | ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy(ADVANCE) | terminated | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 12 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03937141 | Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer | terminated | Phase 2 | 16 | Chinook Therapeutics, Inc. (formerly Aduro)INDUSTRY | 1 | Jan 3, 2022 | clinicaltrials |
| NCT00566540 | Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer | terminated | Phase 2 | 11 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | terminated | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03938337 | Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of Alabama at BirminghamOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03463889 | Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer | terminated | Phase 2 | 12 | University of California, San FranciscoOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT02749227 | Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors(PASSILCORT) | terminated | Phase 2 | 4 | Columbia UniversityOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT03729297 | Cabozantinib in Advanced Salivary Gland Cancer Patients(Cabo ASAP) | terminated | Phase 2 | 25 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT02633540 | Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function | terminated | Phase 2 | 2 | Fox Chase Cancer CenterOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00904345 | Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) | terminated | Phase 2 | 23 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT03887442 | Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy(EXTAX) | terminated | Phase 2 | 17 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 0 | Jan 7, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | terminated | Phase 1 / Phase 2 | 19 | Daiichi SankyoINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02842125 | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | terminated | Phase 1 / Phase 2 | 4 | MultiVir, Inc.INDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01192815 | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT01133678 | Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck | terminated | Phase 2 | 50 | University of ChicagoOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT01111058 | Everolimus Versus Placebo in Head and Neck Cancer | terminated | Phase 2 | 52 | University of ChicagoOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02569788 | Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02801487 | Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 6 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03463161 | Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy(ORKA) | terminated | Phase 2 | 2 | University of ChicagoOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | terminated | Phase 2 | 34 | Eisai Inc.INDUSTRY | 5 | Oct 15, 2019 | clinicaltrials |
| NCT02485470 | Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy | terminated | Phase 2 | 5 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT01230476 | Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma | terminated | Phase 2 | 3 | University of MalayaOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT00408252 | Efficacy of SU 011248 in Head And Neck Carcinoma | terminated | Phase 2 | 54 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 2 | Sep 19, 2019 | clinicaltrials |
| NCT02789189 | Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail | terminated | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 0 | Sep 6, 2019 | clinicaltrials |
| NCT02410382 | Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer | terminated | Phase 2 | 79 | University of ArizonaOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02472080 | Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study(THYGEMOX) | terminated | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT00750555 | Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer | terminated | Phase 2 | 4 | Geisinger ClinicOTHER | 1 | Feb 26, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Nov 4, 2022source: clinicaltrials